Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 45 min ago
Peer-reviewedLicence not statedJournal of Clinical Psychopharmacology

The Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression

  • Mark D. Kvarta1
  • Mai Watanabe2,3
  • Satoshi Ozaki2,3
  • Dede Greenstein1
  • Adam Fijtman1
  • Gregory Jones1
  • Hiroe I. Hu1
  • Solaleh Azimipour1
  • Peixiong Yuan1
  • Jenessa N. Johnston1
  • Jennifer W. Evans1
  • Jessica R. Gilbert1
1 more authors
  • Carlos A. Zarate1
  1. 1Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD
  2. 2Taisho Pharmaceutical R&D Inc., Morristown, NJ
  3. 3Taisho Pharmaceutical Co., Ltd., Tokyo, Japan
Read full textDOICite

Related

  1. Lurasidone Induced Amphibian Like Buccal Oscillations: A Rare Case of Early Onset Tardive Dyskinesia Like Disorder in a Geriatric Patient with Treatment-Resistant Depression
    Ravi Chand Sharma, Ramanpreet Kaur
    Psychopharmacology BulletinPeer-reviewedLicence not statedFull textPsychiatry & mental healthPMC
  2. Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression
    David Feifel, Mathieu Seynaeve, Wiesław Jerzy Cubała +12
    JAMAPeer-reviewedLicence not statedFull text1 citedPsychiatry & mental healthPMC
  3. Individualized, parcel-guided rTMS to the left dorsolateral prefrontal cortex for treatment resistant depression
    J. Berman, D. Q. Truong, A. Murphy +4
    medRxivPreprintCC BYFull textPsychiatry & mental healthmedRxiv
  4. The application of transcranial magnetic stimulation in treatment-resistant depression: insights from omics
    Yuan Yang, Xiaolina Zhang, Yushan Duan +4
    Frontiers in PsychiatryPeer-reviewedCC BY 4.0Full textNeurologyCrossrefEurope PMCPMC
  5. Multimodal predictors of response to intravenous ketamine in treatment-resistant depression: toward personalized treatment in major depressive and bipolar disorders
    Magda Malewska-Kasprzak, Filip Rybakowski, Monika Dmitrzak-Weglarz
    CNS SpectrumsPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyPMC

Cite

BibTeXRIS
BibTeX
@article{kvarta2026antidepressant,
  title = {{The Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression}},
  author = {Mark D. Kvarta and Mai Watanabe and Satoshi Ozaki and Dede Greenstein and Adam Fijtman and Gregory Jones and Hiroe I. Hu and Solaleh Azimipour and Peixiong Yuan and Jenessa N. Johnston and Jennifer W. Evans and Jessica R. Gilbert and Carlos A. Zarate},
  journal = {Journal of Clinical Psychopharmacology},
  year = {2026},
  month = sep,
  doi = {10.1097/jcp.0000000000002246},
  url = {https://doi.org/10.1097/jcp.0000000000002246},
}
RIS
TY  - JOUR
TI  - The Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression
AU  - Mark D. Kvarta
AU  - Mai Watanabe
AU  - Satoshi Ozaki
AU  - Dede Greenstein
AU  - Adam Fijtman
AU  - Gregory Jones
AU  - Hiroe I. Hu
AU  - Solaleh Azimipour
AU  - Peixiong Yuan
AU  - Jenessa N. Johnston
AU  - Jennifer W. Evans
AU  - Jessica R. Gilbert
AU  - Carlos A. Zarate
PY  - 2026
DA  - 2026/09/07
JO  - Journal of Clinical Psychopharmacology
DO  - 10.1097/jcp.0000000000002246
UR  - https://doi.org/10.1097/jcp.0000000000002246
SN  - 0271-0749
SN  - 1533-712X
ER  -